NEW YORK – Cedilla Therapeutics on Monday said it has raised $25 million in an extended Series B financing round, bringing the total funds from the round to $82.6 million.
The funding round included investments from RA Capital Management, Janus Henderson Investors, Woodline Partners, and Logos Capital, and included existing investor Third Rock Ventures. With the funding, Jake Simson, partner at RA Capital Management, will join Cedilla’s board of directors.
Cambridge, Massachusetts-based Cedilla will use the funding to advance its two lead programs, a TEAD inhibitor and a CDK2/Cyclin E inhibitor, which have data suggesting they might work in molecularly defined cancer indications. The TEAD inhibitor is being developed for the treatment of solid tumors, such as mesothelioma and certain squamous cell carcinomas. The CDK2/Cyclin E inhibitor is developed to treat CDK4/6-resistant breast cancer, along with ovarian, uterine, stomach, and esophageal cancers. The funding will also be used to further discovery efforts against other targets.
Cedilla will begin investigational new drug application-enabling studies for the TEAD program in the first half of 2022 and for the CDK2 program in the second half of 2022.
"Preclinical data generated to date suggest that Cedilla's lead programs may challenge historical perceptions of TEAD and CDK2 as undruggable targets and could offer patients new options that would be well-tolerated and extremely effective," Simson said in a statement. "In addition, Cedilla's approach, based on a deep understanding of how the cellular context modulates protein activity, could deliver superior inhibitors against a range of other key cancer drivers."
The company launched in 2018 and has raised about $138 million since its founding.